Compare IPGP & CELC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IPGP | CELC |
|---|---|---|
| Founded | 1990 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.5B | 3.1B |
| IPO Year | 2006 | 2017 |
| Metric | IPGP | CELC |
|---|---|---|
| Price | $72.48 | $100.84 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 8 |
| Target Price | $86.60 | ★ $100.13 |
| AVG Volume (30 Days) | 279.9K | ★ 883.6K |
| Earning Date | 02-10-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.60 | N/A |
| Revenue | ★ $963,643,000.00 | N/A |
| Revenue This Year | $1.84 | N/A |
| Revenue Next Year | $6.52 | N/A |
| P/E Ratio | $120.81 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $48.59 | $7.58 |
| 52 Week High | $92.21 | $112.64 |
| Indicator | IPGP | CELC |
|---|---|---|
| Relative Strength Index (RSI) | 34.43 | 54.64 |
| Support Level | $73.89 | $98.76 |
| Resistance Level | $75.75 | $103.09 |
| Average True Range (ATR) | 2.38 | 4.06 |
| MACD | -0.48 | -1.18 |
| Stochastic Oscillator | 3.35 | 17.60 |
IPG Photonics Corp is a vertically integrated developer and manufacturer of high-performance fiber lasers, fiber amplifiers, and diode lasers, which are used in diverse applications in the manufacturing, automotive, industrial, aerospace, semiconductor, and consumer end markets. The company operates in one segment which involves the design, development, production and distribution of fiber lasers, laser and non-laser systems, fiber amplifiers, and related optical components. A large majority of the firm's revenue is derived from materials processing applications for fiber lasers, including cutting and welding, marking and engraving, and micro-processing. The company generates a majority of its revenue from North America and also has its presence in China, Japan, Germany, and other markets.
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast cancer is currently enrolling patients.